Pooja Mehta1, Zhaoxing Pan2, Stephanie Skirka3, Bethany M Kwan4, Calies Menard-Katcher5. 1. Children's Hospital Colorado, Aurora, CO; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. Electronic address: Pooja.Mehta@childrenscolorado.org. 2. Department of Biostatistics, University of Colorado School of Medicine, Aurora, CO. 3. Children's Hospital Colorado, Aurora, CO. 4. Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO. 5. Children's Hospital Colorado, Aurora, CO; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO.
Abstract
OBJECTIVE: To measure adherence rates to swallowed topical steroids in children with eosinophilic esophagitis (EoE), describe factors related to adherence, and determine the association between adherence, symptoms, perceived disease severity, and quality of life in children with EoE. STUDY DESIGN: Subjects in this cross-sectional study of 117 children between 5 and 18 years old with EoE completed the Pediatric Eosinophilic Esophagitis Symptoms Score V2.0 (PEESS), Pediatric Quality of Life Inventory Eosinophilic Esophagitis Module (PedsQL EoE), a Medication-Taking Checklist (MTC), and a demographics questionnaire. Adherence rate was calculated based on reported number of missed doses/prescribed doses in the last week. Parent-reported measures were used for children aged 5-12 years and self-report was used for children aged 13-18 years. RESULTS: Adolescents had lower adherence rates than younger children (76.2 ± 24.5% vs 88.6 ± 16.7%, P = .002). Adherence rates were not associated with disease history, PEESS, or PedsQL EoE scores but instead correlated with MTC scores (Pearson r of 0.65, P < .001 for child-report and Pearson r of 0.74, P < .001 for parent-report). Symptomatology was associated with worse quality of life (PEESS Frequency: r = -0.7, P < .001; PEESS Severity: r = -0.71, P < .001 for children 5-12 years old; PEESS Frequency: r = -0.61, P < .001; PEESS Severity: r = -.5, P < .001 for adolescents). CONCLUSIONS: Unrelated to their clinical history, demographic factors, symptoms, and quality of life, adolescents with EoE have lower medication adherence rates. The MTC may serve as a clinical tool to discuss adherence and provide targeted educational counseling regarding adherence interventions.
OBJECTIVE: To measure adherence rates to swallowed topical steroids in children with eosinophilic esophagitis (EoE), describe factors related to adherence, and determine the association between adherence, symptoms, perceived disease severity, and quality of life in children with EoE. STUDY DESIGN: Subjects in this cross-sectional study of 117 children between 5 and 18 years old with EoE completed the Pediatric Eosinophilic Esophagitis Symptoms Score V2.0 (PEESS), Pediatric Quality of Life Inventory Eosinophilic Esophagitis Module (PedsQL EoE), a Medication-Taking Checklist (MTC), and a demographics questionnaire. Adherence rate was calculated based on reported number of missed doses/prescribed doses in the last week. Parent-reported measures were used for children aged 5-12 years and self-report was used for children aged 13-18 years. RESULTS: Adolescents had lower adherence rates than younger children (76.2 ± 24.5% vs 88.6 ± 16.7%, P = .002). Adherence rates were not associated with disease history, PEESS, or PedsQL EoE scores but instead correlated with MTC scores (Pearson r of 0.65, P < .001 for child-report and Pearson r of 0.74, P < .001 for parent-report). Symptomatology was associated with worse quality of life (PEESS Frequency: r = -0.7, P < .001; PEESS Severity: r = -0.71, P < .001 for children 5-12 years old; PEESS Frequency: r = -0.61, P < .001; PEESS Severity: r = -.5, P < .001 for adolescents). CONCLUSIONS: Unrelated to their clinical history, demographic factors, symptoms, and quality of life, adolescents with EoE have lower medication adherence rates. The MTC may serve as a clinical tool to discuss adherence and provide targeted educational counseling regarding adherence interventions.
Authors: Ana M Gutiérrez-Colina; Cyd K Eaton; Jennifer L Lee; Bonney Reed-Knight; Kristin Loiselle; Laura L Mee; Julia LaMotte; Rochelle Liverman; Ronald L Blount Journal: J Pediatr Psychol Date: 2015-11-13
Authors: Seema S Aceves; Eileen King; Margaret H Collins; Guang-Yu Yang; Kelley E Capocelli; J Pablo Abonia; Dan Atkins; Peter A Bonis; Christina L Carpenter; Evan S Dellon; Michael D Eby; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Kendra Kocher; Jeffrey P Krischer; John Leung; Jessi Lipscomb; Paul Menard-Katcher; Vincent A Mukkada; Zhaoxing Pan; Jonathan M Spergel; Qin Sun; Barry K Wershil; Marc E Rothenberg; Glenn T Furuta Journal: J Allergy Clin Immunol Date: 2018-05-29 Impact factor: 10.793
Authors: Lisa J Martin; James P Franciosi; Margaret H Collins; J Pablo Abonia; James J Lee; Kevin A Hommel; James W Varni; J Tommie Grotjan; Michael Eby; Hua He; Keith Marsolo; Philip E Putnam; Jose M Garza; Ajay Kaul; Ting Wen; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2015-06 Impact factor: 10.793
Authors: Vicente Plaza; Concepción Fernández-Rodríguez; Carlos Melero; Borja G Cosío; Luís Manuel Entrenas; Luis Pérez de Llano; Fernando Gutiérrez-Pereyra; Eduard Tarragona; Rosa Palomino; Antolín López-Viña Journal: J Aerosol Med Pulm Drug Deliv Date: 2015-07-31 Impact factor: 2.849